JUBLPHARMAPharmaceuticals
Jubilant Pharmova Ltd — Cash Flow Statement
₹816.45
-1.80%
Jubilant Pharmova Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Issuance Of Capital Stock | 0.90 Cr | 0.00 | — | 0.00 | -10.06 Cr |
| Capital Expenditure | -1.12K Cr | -897.70 Cr | -814.50 Cr | -599.99 Cr | — |
| End Cash Position | 1.09K Cr | 956.40 Cr | 1.01K Cr | 983.82 Cr | — |
| Beginning Cash Position | 956.40 Cr | 1.01K Cr | 983.80 Cr | 501.96 Cr | — |
| Effect Of Exchange Rate Changes | 24.80 Cr | 11.60 Cr | 70.50 Cr | 57.29 Cr | — |
| Changes In Cash | 107.10 Cr | -69.10 Cr | -40.40 Cr | 424.57 Cr | — |
| Financing Cash Flow | -1.45K Cr | -432.50 Cr | -156.70 Cr | -32.60 Cr | — |
| Interest Paid Cff | -235.60 Cr | -243.70 Cr | -234.20 Cr | -134.94 Cr | — |
| Cash Dividends Paid | -79.60 Cr | -79.80 Cr | -80.10 Cr | -80.05 Cr | — |
| Common Stock Dividend Paid | -79.60 Cr | -79.80 Cr | -80.10 Cr | -80.05 Cr | — |
| Net Common Stock Issuance | -4.70 Cr | -27.40 Cr | -4.00 Cr | 0.00 | — |
| Common Stock Payments | -5.60 Cr | -27.40 Cr | -4.00 Cr | 0.00 | — |
| Common Stock Issuance | 0.90 Cr | 0.00 | — | 0.00 | -10.06 Cr |
| Net Issuance Payments Of Debt | -1.07K Cr | -20.40 Cr | 231.70 Cr | 242.18 Cr | — |
| Net Short Term Debt Issuance | 22.50 Cr | -61.70 Cr | 194.30 Cr | 44.00 Cr | — |
| Net Long Term Debt Issuance | -1.10K Cr | 41.30 Cr | 37.40 Cr | 198.18 Cr | — |
| Long Term Debt Payments | -1.10K Cr | -75.90 Cr | -2.77K Cr | -5.00 Cr | — |
| Long Term Debt Issuance | 4.90 Cr | 117.20 Cr | 2.81K Cr | 203.18 Cr | — |
| Investing Cash Flow | 487.70 Cr | -607.90 Cr | -544.40 Cr | -380.37 Cr | — |
| Net Other Investing Changes | 609.20 Cr | 229.70 Cr | 244.50 Cr | 170.29 Cr | — |
| Interest Received Cfi | 38.40 Cr | 25.70 Cr | 10.00 Cr | 4.02 Cr | — |
| Dividends Received Cfi | 0.00 | 26.80 Cr | 8.80 Cr | 0.00 | — |
| Net Investment Purchase And Sale | 950.70 Cr | -2.10 Cr | -11.80 Cr | 212.08 Cr | — |
| Sale Of Investment | 952.10 Cr | 5.70 Cr | 0.90 Cr | 214.40 Cr | — |
| Purchase Of Investment | -1.40 Cr | -7.80 Cr | -12.70 Cr | -2.32 Cr | — |
| Net PPE Purchase And Sale | -1.11K Cr | -888.00 Cr | -795.90 Cr | -596.47 Cr | — |
| Sale Of PPE | 5.00 Cr | 9.70 Cr | 18.60 Cr | 3.52 Cr | — |
| Purchase Of PPE | -1.12K Cr | -897.70 Cr | -814.50 Cr | -599.99 Cr | — |
| Operating Cash Flow | 1.07K Cr | 971.30 Cr | 660.70 Cr | 837.54 Cr | — |
| Taxes Refund Paid | -238.40 Cr | -207.70 Cr | -204.30 Cr | -194.09 Cr | — |
| Change In Working Capital | 111.80 Cr | 253.10 Cr | 54.30 Cr | -178.29 Cr | — |
| Change In Other Current Liabilities | -17.00 Cr | 32.90 Cr | -274.20 Cr | -42.87 Cr | — |
| Change In Payable | 55.30 Cr | 23.20 Cr | 210.50 Cr | 0.16 Cr | — |
| Change In Inventory | 78.50 Cr | 90.80 Cr | -64.70 Cr | -95.65 Cr | — |
| Change In Receivables | -5.00 Cr | 106.20 Cr | 182.70 Cr | -39.93 Cr | — |
| Other Non Cash Items | -155.80 Cr | 415.10 Cr | 235.20 Cr | 143.03 Cr | — |
| Stock Based Compensation | 4.30 Cr | 8.50 Cr | 3.70 Cr | 1.12 Cr | — |
| Depreciation And Amortization | 368.60 Cr | 381.90 Cr | 554.00 Cr | 381.70 Cr | — |
| Depreciation | 368.60 Cr | 381.90 Cr | 316.10 Cr | 292.16 Cr | — |
| Gain Loss On Investment Securities | 1.70 Cr | -0.20 Cr | 5.00 Cr | -0.15 Cr | — |
| Net Foreign Currency Exchange Gain Loss | 0.10 Cr | 1.40 Cr | -5.40 Cr | 40.41 Cr | — |
| Gain Loss On Sale Of PPE | -1.30 Cr | -0.20 Cr | 2.70 Cr | 3.37 Cr | — |
| Net Income From Continuing Operations | 980.60 Cr | 170.50 Cr | 27.80 Cr | 630.45 Cr | — |
| Free Cash Flow | -43.50 Cr | 73.60 Cr | -153.80 Cr | 237.55 Cr | — |
| Repurchase Of Capital Stock | -5.60 Cr | -27.40 Cr | -4.00 Cr | 0.00 | — |
| Repayment Of Debt | -1.10K Cr | -75.90 Cr | -2.77K Cr | -5.00 Cr | — |
| Issuance Of Debt | 4.90 Cr | 117.20 Cr | 2.81K Cr | 203.18 Cr | — |
| Amortization Cash Flow | — | 52.10 Cr | 237.90 Cr | 89.55 Cr | 88.50 Cr |
| Other Cash Adjustment Outside Changein Cash | — | — | — | — | -76.98 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Jubilant Pharmova Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.